A 38-year-old woman with moderate persistent asthma is started on budesonide inhaled corticosteroid. Which feature best distinguishes budesonide from mometasone furoate in terms of clinical pharmacology?

Explanation

## Comparison: Budesonide vs Mometasone Furoate ### Lung Deposition & Intrapulmonary Residence Time | Feature | Budesonide | Mometasone Furoate | |---------|-----------|-------------------| | **Lipophilicity** | Moderate | Very high (among highest of ICS) | | **Lung Deposition** | ~28–32% (DPI) | ~17–25% (MDI); but higher intrapulmonary retention due to lipophilicity | | **Intrapulmonary Residence Time** | Shorter | Longer (due to high lipophilicity → tissue binding) | | **Systemic Bioavailability** | ~10–15% (oral fraction) | ~0.1% (negligible) | | **First-Pass Metabolism** | Extensive (CYP3A4) | Minimal | | **Onset of Action** | 24–48 hours | 24–48 hours | **Key Point:** Mometasone furoate's defining pharmacokinetic feature is its exceptionally high lipophilicity, which confers greater lung tissue binding and a longer intrapulmonary residence time compared to budesonide. This sustained local retention contributes to prolonged anti-inflammatory action and reduced systemic absorption [KD Tripathi 8e Ch 28; Derendorf & Nave, Respir Med 2006]. ### Clinical Significance **High-Yield:** Mometasone's high lipophilicity means: - Prolonged retention in airway tissue → sustained local glucocorticoid receptor occupancy - Negligible systemic bioavailability (~0.1%) — one of the lowest among ICS agents - Once-daily dosing feasible due to prolonged intrapulmonary residence - Minimal HPA axis suppression at standard doses **Clinical Pearl:** Among inhaled corticosteroids, lipophilicity rank (high to low): fluticasone furoate > mometasone > fluticasone propionate > budesonide > beclomethasone. Higher lipophilicity generally correlates with longer intrapulmonary residence time and lower systemic bioavailability. --- ## Why the Other Options Are Incorrect **Option A** is false: Both budesonide and mometasone have similar onset of action (24–48 hours for clinical effect). Neither is appropriate for acute exacerbations — both are maintenance/controller agents only. **Option C** is inaccurate: Budesonide is available as DPI (Turbuhaler), nebulized suspension, AND MDI formulations. Mometasone is available as both MDI (Asmanex HFA) and DPI (Asmanex Twisthaler). The claim that each is limited to a single device type is incorrect. **Option D** is partially true but misleading as the *distinguishing* feature: While budesonide does undergo extensive CYP3A4 first-pass metabolism (~10–15% systemic bioavailability), mometasone also has very low systemic bioavailability (~0.1%) — but this is due to negligible GI absorption and high lipophilicity, not primarily due to hepatic metabolism. More importantly, the statement that mometasone "undergoes minimal metabolism" conflates low systemic absorption with low hepatic metabolism, making this option pharmacokinetically imprecise as a distinguishing feature. The more clinically validated and textbook-supported distinction is mometasone's superior intrapulmonary residence time due to high lipophilicity. --- **Mnemonic:** **MOM STAYS LONGER** — Mometasone's high lipophilicity means it stays longer in lung tissue, providing sustained local action with minimal systemic escape.